Aemetis (AMTX) Scheduled to Post Earnings on Thursday

Aemetis (NASDAQ:AMTX – Get Rating) is set to post its quarterly earnings results before the market opens on Thursday, March 9th. Analysts expect Aemetis to post earnings of ($0.28) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Aemetis Stock Down 1.9 %

NASDAQ AMTX opened at $3.61 on Wednesday. The firm has a market cap of $126.49 million, a price-to-earnings ratio of -1.39 and a beta of 0.87. The business has a 50-day moving average price of $4.14 and a 200-day moving average price of $5.68. Aemetis has a twelve month low of $3.53 and a twelve month high of $16.06.

Hedge Funds Weigh In On Aemetis

A number of large investors have recently bought and sold shares of the business. State Street Corp raised its position in Aemetis by 9.6% in the first quarter. State Street Corp now owns 1,998,092 shares of the specialty chemicals company’s stock worth $25,316,000 after acquiring an additional 175,009 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Aemetis in the 3rd quarter valued at approximately $1,008,000. Millennium Management LLC lifted its stake in shares of Aemetis by 14.5% in the 4th quarter. Millennium Management LLC now owns 1,007,208 shares of the specialty chemicals company’s stock valued at $3,989,000 after purchasing an additional 127,674 shares during the last quarter. ExodusPoint Capital Management LP boosted its stake in shares of Aemetis by 223.1% during the 4th quarter. ExodusPoint Capital Management LP now owns 180,050 shares of the specialty chemicals company’s stock worth $713,000 after acquiring an additional 124,319 shares in the last quarter. Finally, BlackRock Inc. grew its holdings in Aemetis by 3.3% during the first quarter. BlackRock Inc. now owns 3,086,834 shares of the specialty chemicals company’s stock valued at $39,112,000 after purchasing an additional 99,903 shares during the last quarter. Institutional investors own 50.72% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Ascendiant Capital Markets dropped their target price on Aemetis to $26.00 in a report on Wednesday, November 16th. Piper Sandler initiated coverage on Aemetis in a report on Monday, February 27th. They issued an “underweight” rating and a $3.00 price target for the company. Truist Financial cut their price target on shares of Aemetis from $9.00 to $5.00 and set a “hold” rating for the company in a report on Wednesday, February 1st. Finally, UBS Group assumed coverage on shares of Aemetis in a research report on Tuesday, December 13th. They issued a “neutral” rating and a $4.25 target price on the stock. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $13.05.

About Aemetis

(Get Rating)

Aemetis, Inc is a renewable fuels and biochemical company, which engages in the acquisition, development, and commercialization of technologies that replace traditional petroleum-based products. It operates through the North America and India geographical segments. The North America segment manages Keyes Plant in California, the cellulosic ethanol facility in Riverbank, the cluster of biogas digesters on dairies near Keyes, California, the Goodland Plant, Kansas and the research and development facility in Minnesota.